The Cigna Group

Company Overview

Business Model: The Cigna Group is a global health company that provides a differentiated set of pharmacy, medical, behavioral, dental, and related products and services through its subsidiaries. The Evernorth Health Services segment offers independent and coordinated health solutions, including pharmacy benefit management, specialty pharmacy, specialty distribution, and care services. The Cigna Healthcare segment provides comprehensive medical and coordinated solutions, including medical plans and other benefits for insured and self-insured clients, as well as individual and family plan customers in the U.S. and international markets. The Company generates revenue primarily through fees for administrative services (ASO) and premiums for insured plans, combining pharmacy and medical capabilities to improve affordability, transparency, and health outcomes.

Market Position: The Cigna Group serves over 185 million customer relationships across more than 30 markets and jurisdictions globally, supported by approximately 67,700 colleagues as of December 31, 2025. The Company maintains approximately 1.7 million relationships with health care providers, clinics, and facilities. Key competitive advantages include its health advocacy capabilities, holistic approach to consumer engagement, broad product offerings, and clinical care and health management capabilities. The U.S. network comprises approximately 1.7 million physicians and over 6,000 hospitals. The Company engages in more than 200 value-based payment arrangements with primary care groups, approximately 100 with specialist groups, and contracts with over 200 hospital systems involving more than 750 hospitals, with reimbursements tied to quality metrics.

Recent Strategic Developments:

• Divestiture of Medicare Advantage and Related Businesses: On March 19, 2025, The Cigna Group completed the sale of its Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies businesses to Health Care Service Corporation. The final purchase price and total cash proceeds collected in 2025 were $4.9 billion.
• Strategic Optimization Program: In the first quarter of 2025, the Company initiated an enterprise-wide program to enhance business efficiency and improve patient, provider, and customer experiences. This multiyear initiative is expected to generate annualized after-tax savings of at least $500 million and is anticipated to continue through 2028.
• Rebate-free Pharmacy Benefits Model: Evernorth Health Services announced a new pharmacy benefits model designed to provide upfront discounts negotiated with drug companies directly to customers, aiming to lower out-of-pocket costs and increase transparency. Cigna Healthcare plans to adopt this model for its fully insured customers starting in 2027, and it will become the standard for Evernorth Health Services pharmacy benefit clients beginning in 2028.
• Investment in Shields Health Solutions: In August 2025, The Cigna Group borrowed $2.0 billion to partially fund an investment in Shields Health Solutions, a specialty pharmacy management company. In the third quarter of 2025, the Company invested $3.5 billion in preferred stock of Shields Health Solutions.

Geographic Footprint: The Cigna Group operates in over 30 markets and jurisdictions globally. Approximately 88% of its 67,700 employees are based in the United States. U.S. external customers accounted for 98% of total revenues from external customers in 2025. Consolidated pre-tax income from foreign operations represented approximately 53% of the Company's total pre-tax income in 2025. International Health offerings are provided in various countries, including China, Singapore, Hong Kong, Spain, and India, along with countries in the Middle East. The Company's domestic real estate portfolio spans approximately 6.3 million square feet across 42 states, the District of Columbia, and the U.S. Virgin Islands, with international properties totaling approximately 1.8 million square feet across 23 countries.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 9.3%
• Operating Margin: 3.3%
• Net Margin: 2.2%

Investment in Growth:

• R&D Expenditure: Not explicitly disclosed as a separate line item.
• Capital Expenditures: $1.2 billion (2025) ($1.4 billion in 2024)
• Strategic Investments: $3.5 billion investment in preferred stock of Shields Health Solutions in 2025.

Business Segment Analysis

Evernorth Health Services

Financial Performance:

• Revenue: $234.9 billion (+16.2% YoY)
• Operating Margin: 3.1% (pre-tax adjusted income from operations / adjusted revenues)
• Key Growth Drivers: Primarily driven by higher utilization of prescription drugs from customer growth in Pharmacy Benefit Services (+6%) and Specialty and Care Services (+6%), and an increase due to claims composition in Pharmacy Benefit Services (+4%). Specialty pharmacy growth in Specialty and Care Services (+6%) and contract affordability improvements and customer growth in Pharmacy Benefit Services (+1%) also contributed.

Product Portfolio:

• Pharmacy Benefit Services: Offers pharmacy benefits including retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, medical drug management, and administration of group purchasing organizations. Value-based programs include SafeGuardRx, Express Scripts Patient Assurance, Evernorth EncircleRx, and Evernorth EnReachRx. The Evernorth Wholesale Marketplace provides flexible PBM solutions. The segment also includes Home Delivery Pharmacy services through Express Scripts Pharmacy and Evernorth EnGuide Pharmacy, which was established in 2025 to support customers prescribed GLP-1 medications.
• Specialty and Care Services: Provides specialty medications for complex and rare diseases through Accredo Specialty Pharmacy's Therapeutic Resource Centers. Health System Services, including CuraScript SD by Evernorth, distributes pharmaceuticals and medical supplies to healthcare providers. Care Services offers clinical programs such as MD Live by Evernorth virtual care and EviCore by Evernorth benefits management, behavioral health services, network services, and health coaching.

Market Dynamics:

• Evernorth Health Services serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, and hospitals.
• Key clients include Centene Corporation, Prime Therapeutics LLC, and The Department of War TRICARE.
• A single pharmacy benefit client accounted for approximately 19% of total external revenues in 2025.

Cigna Healthcare

Financial Performance:

• Revenue: $47.2 billion (-10.9% YoY)
• Operating Margin: 8.8% (pre-tax adjusted income from operations / adjusted revenues)
• Key Growth Drivers: The decrease in revenue was primarily due to the divestiture of Medicare Advantage and related businesses (-$8.5 billion), partially offset by higher premiums in employer insured (+$1.3 billion) and stop loss (+$0.9 billion) businesses, reflecting premium rate increases. Pre-tax adjusted income from operations decreased due to lower contributions from the Individual and Family Plans business. The medical care ratio increased by 120 basis points to 84.4%, primarily due to higher medical costs in the Individual and Family Plans business.

Product Portfolio:

• U.S. Healthcare Medical Plans: Includes employer medical plans (Open Access Plus, LocalPlus, HMO, PPO) with various funding options (ASO, insured guaranteed cost, insured experience rated). Consumer-driven products like Health Savings Accounts, Health Reimbursement Accounts, and Flexible Spending Accounts are also offered. Individual and Family Plans (IFP) are ACA-compliant EPOs or HMO plans offered in 11 states.
• U.S. Healthcare Benefits and Solutions: Offers behavioral health solutions, consumer health engagement programs, cost containment programs, dental solutions (HMO, PPO, EPO, indemnity, discount programs), pharmacy management solutions leveraging Evernorth Health Services capabilities, and stop-loss insurance.
• International Health: Provides global health care offerings (medical, dental, pharmacy, vision, life, accidental death and dismemberment, disability) for multinational employers and globally mobile individuals. Local health care offerings are available in specific geographies (China, Singapore, Hong Kong, Spain, India, and the Middle East).

Market Dynamics:

• Cigna Healthcare serves employers, third-party administrators, union-sponsored benefit plans, and individuals.
• Medical customers totaled 18.1 million as of December 31, 2025, a 5% decrease from 2024, primarily due to the HCSC transaction.
• ASO arrangements represented approximately 32% of 2025 segment revenues and 79% of Cigna Healthcare medical customers. Insured arrangements accounted for approximately 68% of 2025 segment revenues and 21% of medical customers.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: The Company repurchased 11.9 million shares for approximately $3.6 billion during 2025, compared to 20.9 million shares for approximately $7.0 billion in 2024.
• Dividend Payments: The Cigna Group declared and paid quarterly cash dividends of $1.51 per share of common stock in 2025, totaling $1.61 billion.
• Future Capital Return Commitments: The Board of Directors declared a first-quarter 2026 cash dividend of $1.56 per share. The Company intends to pay regular quarterly dividends, subject to Board approval. A share repurchase program is authorized by the Board, with timing and amounts dependent on market conditions and alternative capital uses.

Balance Sheet Position:

• Cash and Equivalents: $7.7 billion (2025)
• Total Debt: $31.5 billion (2025)
• Net Cash Position: -$23.8 billion (Net Debt)
• Credit Rating: Not disclosed in the filing.
• Debt Maturity Profile: Total scheduled payments on long-term debt are $49.9 billion through January 2056. Key maturities include $0.6 billion in 2026, $2.4 billion in 2027, $3.8 billion in 2028, $1.0 billion in 2029, and $2.4 billion in 2030.

Cash Flow Generation:

• Operating Cash Flow: $9.6 billion (2025) ($10.4 billion in 2024)
• Free Cash Flow: Not explicitly disclosed.
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: The Cigna Group's operational philosophy centers on cultivating robust, innovative digital-first capabilities to enhance customer and stakeholder engagement. The Company's pharmacy technology platform processes over two billion adjusted prescriptions annually, enabling safe, rapid, and accurate claim adjudication. This includes real-time safety checks to prevent medication errors. The Company is committed to reimagining operating models, products, and interactions to create new value, leveraging augmented intelligence to support healthcare transformation and personalize solutions.

Supply Chain Architecture:

• Key Suppliers & Partners: The Company purchases pharmaceuticals directly from manufacturers or through authorized wholesalers, with one wholesaler accounting for approximately half of its pharmaceutical purchases. Health System Services acts as a contracted supplier with most major group purchasing organizations and a third-party logistics provider for pharmaceutical companies. The Company relies on a national network of participating healthcare providers and maintains strategic alliances with regional managed care organizations for network access and discounts. Technology systems interface with and depend on third-party systems, and the Company requires suppliers accessing, hosting, or transmitting its data to comply with its Security Policies and Standards.

Facility Network:

• Manufacturing: Evernorth Health Services operates 11 licensed home delivery pharmacies (including four fulfillment pharmacies in Arizona, Indiana, Missouri, and New Jersey), two licensed Evernorth EnGuide Pharmacy facilities (including one fulfillment pharmacy in Ohio), and 35 licensed specialty pharmacies.
• Research & Development: While specific R&D facilities are not detailed, the Company emphasizes its "Research & Development Focus" on core technology areas and innovation pipeline.
• Distribution: Health System Services operates four distribution centers, primarily shipping products overnight within the United States.
• Office Locations: The Company's global real estate portfolio includes approximately 8.1 million square feet of owned and leased properties. Principal domestic offices include the corporate headquarters in Bloomfield, Connecticut (owned), Evernorth Health Services' leased offices in St. Louis, Missouri, and leased office space in Philadelphia, Pennsylvania.

Operational Metrics:

• Pharmacy Claim Volume: 2,222 million adjusted claims (2025), representing a 5% increase year-over-year.
• Cigna Healthcare Medical Care Ratio: 84.4% (2025)
• Cigna Healthcare SG&A Expense Ratio: 20.2% (2025)
• Evernorth Health Services SG&A Expense Ratio: 1.8% (2025)

Market Access & Customer Relationships

Go-to-Market Strategy:

• Distribution Channels: The Cigna Group employs a multifaceted approach to market access. Direct sales are conducted by Cigna Healthcare sales representatives to employers, unions, and other groups or individuals. The Company also leverages a broad network of brokers and consultants for product and solution distribution. For individual health insurance, Cigna Healthcare partners with select private exchanges and offers ACA-compliant policies through public health insurance exchanges in specific geographies.
• Digital Platforms: The Company's digital strategy focuses on transitioning from analog to digital, creating efficiencies, and enhancing existing offerings through personalization and AI-driven solutions for customers, clients, and providers.

Customer Portfolio:

• Enterprise Customers: Evernorth Health Services has significant relationships with Centene Corporation, Prime Therapeutics LLC, and the Department of War TRICARE. The Cigna Group engages in value-based payment arrangements with over 200 primary care groups, approximately 100 specialist groups, and more than 200 hospital systems.
• Customer Concentration: A single pharmacy benefit client accounted for approximately 19% of total external revenues in 2025. Revenues from U.S. Federal Government agencies were less than 10% of total external revenues in 2025.
• Medical Customers: Total medical customers for Cigna Healthcare were 18.1 million as of December 31, 2025, with 14.3 million served through Administrative Services Only (ASO) arrangements and 3.8 million through insured plans.

Geographic Revenue Distribution: U.S. external customers generated 98% of total revenues from external customers in 2025. The Company's international operations contribute significantly to pre-tax income, accounting for approximately 53% of consolidated pre-tax income in 2025.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The Cigna Group operates in a highly competitive, evolving, and rapidly changing industry. Key dynamics include ongoing consolidation among industry participants (insurers, providers, pharmaceutical manufacturers), the emergence of new business models and market entrants, and rapid technological advancements such as telehealth and artificial intelligence. The industry is also significantly influenced by legislative, executive, and regulatory changes, particularly concerning drug pricing and insurance market reforms.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Evernorth Health Services: Competes with independent and managed care pharmacy benefit managers, retail, home delivery, and specialty pharmacies, specialty drug distributors, health plans, third-party benefit administrators, group purchasing organizations, clinical solutions companies, health care data analytics companies, and care services providers.
• Cigna Healthcare: Competes with national insurers, local health plans, third-party administrators, dental insurers, independent and managed care pharmacy benefit managers, global insurers, and local non-U.S. insurers.

Emerging Competitive Threats: The Company faces threats from new market entrants, including those not traditionally in the health services industry, and the potential for disruptive technologies and alternative business models. The increasing use of AI by competitors and the evolving regulatory landscape around AI also pose competitive challenges.

Competitive Response Strategy: The Cigna Group's strategy focuses on differentiating itself through its mission to improve health and vitality, executing its "Commitments to Better" initiative, and investing in innovative, cost-effective product and service offerings. This includes developing a transparent rebate-free model for pharmacy benefits and continuously enhancing technology systems to anticipate customer needs and improve the customer experience.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Profitability is highly dependent on accurately predicting and managing healthcare costs, responding to intense price competition, and adapting to external factors like new treatments, provider billing practices, and inflation. Failure to maintain or renew contracts with large clients or pharmaceutical manufacturers could materially impact results. The inherent variability in estimating medical claims reserves also poses a risk if actual claims exceed estimates.
• Technology Disruption: Rapid shifts in technology, including telehealth and AI, can alter industry dynamics. The Company's use of AI and machine learning technologies presents regulatory and legal challenges, including risks of inaccurate or biased outputs, which could negatively affect its business and reputation.
• Customer Concentration: Revenues from a single pharmacy benefit client represented approximately 19% of total external revenues in 2025, indicating a concentration risk if this relationship is terminated or renegotiated unfavorably.

Operational & Execution Risks

• Supply Chain Vulnerabilities: The business relies heavily on efficient and uninterrupted performance of critical functions (e.g., claims processing, home delivery) and the availability of services and products from key suppliers, providers, and pharmaceutical manufacturers. Disruptions in the supply chain, including those from natural disasters or cyberattacks on third-party vendors, could materially affect operations.
• Geographic Concentration: Increasing natural disasters linked to climate change pose a direct threat to operations and third-party vendors in affected regions.
• Capacity Constraints: Dependence on third-party systems and potential for service denials if demand exceeds capacity or systems fail could disrupt operations.

Financial & Regulatory Risks

• Market & Financial Risks: Economic and market conditions, including stock market or interest rate declines, can impact investment values, pension obligations, and the cost of borrowed funds. A downgrade in financial strength or debt ratings could adversely affect sales, capital access, and borrowing costs. Significant indebtedness could limit financial flexibility. The Company is also exposed to credit risk from its reinsurers.
• Regulatory & Compliance Risks: The business is subject to extensive and complex federal, state, and international regulations, including healthcare fraud and abuse laws, privacy and data security laws (e.g., HIPAA, GDPR), and government procurement regulations. Noncompliance or changes in these regulations could lead to fines, penalties, litigation, restrictions on operations, or reputational harm. Participation in government-sponsored programs carries risks related to funding dependence and increased regulatory oversight.

Geopolitical & External Risks

• Geopolitical Exposure: International operations expose the Company to political, legal, operational, regulatory, and economic risks, including foreign currency exchange fluctuations and local civil unrest. Operating in new foreign markets requires significant management resources.
• Trade Relations: Geopolitical developments and trade tensions can impact international operations and regulatory dynamics.
• Sanctions & Export Controls: Compliance with U.S. Office of Foreign Assets Control sanctions, the Foreign Corrupt Practices Act, and other anti-corruption and anti-money laundering laws in foreign jurisdictions is critical, with violations potentially leading to severe penalties and reputational damage.

Innovation & Technology Leadership

Research & Development Focus: The Cigna Group is strategically investing in digital, data, and technology to cultivate robust, innovative digital-first capabilities. A core focus is on leveraging artificial intelligence (AI) and machine learning (ML) to transform healthcare by enabling accessible, effective, affordable, and enhanced solutions. The Company utilizes AI models for personalized solutions, earlier interventions, and simplified healthcare experiences, often as "augmented intelligence" to support human experts.

Innovation Pipeline: The Company fosters a culture of innovation and enablement, empowering teams to challenge conventions and experiment with new ways to engage customers, close care gaps, optimize treatment, and improve outcomes. This includes reimagining operating models, products, and interactions to create new sources of value. The Enterprise Model Governance (EMG) team and the AI Center of Enablement (AI COE) oversee the responsible development and deployment of AI models, adhering to principles of validity, reliability, safety, privacy, fairness, transparency, and accountability.

Intellectual Property Portfolio: The Cigna Group holds over 540 U.S. patents, which are used to protect proprietary technological advances and differentiate the Company in the market. The Company states it is not substantially dependent on any single patent or group of related patents and is not aware of any facts that could materially impact the continuing use of its intellectual property.

Technology Partnerships: The Company engages in strategic alliances and research collaborations to develop and create responsible data and analytic solutions. These partnerships support and improve outcomes for its products, services, and solutions, contributing to its overall innovation strategy.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Cigna Group has a leadership development strategy, anchored by The Cigna Group Leader Profile, to cultivate leadership capabilities and ensure continuity across the organization. Board Composition: The Board of Directors provides ultimate oversight of privacy and cybersecurity programs and strategy. Certain Board members hold cybersecurity certifications. In 2025, oversight was conducted through the Audit Committee (cybersecurity) and Compliance Committee (privacy). Beginning in 2026, cybersecurity oversight transitioned to the Board's Finance & Technology Committee.

Human Capital Strategy

Workforce Composition: As of the end of 2025, The Cigna Group employed approximately 67,700 employees worldwide, with about 88% based in the United States. Approximately 97% of the workforce is full-time. The global workforce is composed of approximately 69% women and 31% men, and about 40% of U.S. employees identify as ethnic minorities.

Talent Management:

• Acquisition & Retention: The Company's talent acquisition and rewards strategies aim to attract and retain skilled employees. The voluntary turnover rate in 2025 was approximately 9%. Compensation practices are rooted in a pay-for-performance philosophy, ensuring fair and competitive pay. Within the U.S., female employees and employees from underrepresented groups earn more than 99 cents for every dollar earned by similarly situated male and white employees, respectively.
• Diversity & Development: The Cigna Group offers a broad range of training, education, and development resources through its online learning platform and career development tools. In 2025, employees engaged in an average of 45 hours of learning. Leadership development programs cultivate capabilities aligned with the Company's mission and goals. An education reimbursement program is also available for eligible employees.
• Culture & Engagement: The Company prioritizes and invests in employee health and vitality, allocating approximately 20% of total payroll to health, well-being, and other benefits in 2025. Multidimensional wellness programs support physical, mental, financial, and social health.

Environmental & Social Impact

Environmental Commitments:

• Climate Strategy: The Cigna Group believes in responsible environmental stewardship to improve health and vitality and make sound business sense. The Company strives to identify efficiencies and make strategic investments to reduce its environmental impacts and operating costs. No specific emissions targets or carbon neutrality commitments are disclosed in the filing.
• Supply Chain Sustainability: The Company is committed to supporting a responsible supply chain. No specific details on supplier engagement or responsible sourcing initiatives are provided.

Social Impact Initiatives:

• Community Investment: The Company engages in charitable giving and volunteerism in communities globally where it operates.
• Product Impact: The Cigna Group is committed to understanding and addressing social determinants of health, improving medical quality and access, lowering health risks, promoting preventive health interventions, and coordinating care. This is achieved by aligning products and services with value-based care models, leveraging integrated benefits, managing drug costs through innovation, expanding digital offerings, and reviewing coverage policies for health equity.

Business Cyclicality & Seasonality

Demand Patterns: The Company's profitability is sensitive to economic conditions, which can impact client and customer behavior, healthcare utilization patterns, and provider financial stability. Higher unemployment rates or workforce reductions could lead to lower enrollment in employer-based or individual plans. Planning & Forecasting: The Cigna Group's financial performance depends on its ability to accurately predict, price for, and effectively manage future healthcare costs and utilization rates. Timely anticipation and detection of medical cost trends are crucial for taking corrective actions and reflecting current benefit cost experience in pricing.

Regulatory Environment & Compliance

Regulatory Framework: The Cigna Group operates under extensive federal, state, and international regulations. Key regulatory bodies include HHS, CMS, IRS, DOL, OPM, DHA, FTC, SEC, state departments of insurance, and state boards of pharmacy. International operations are subject to rigorous regulations and geopolitical dynamics. The Company's business practices are also shaped by enforcement actions and judicial decisions. Industry-Specific Regulations: These include laws governing pharmacy benefit manager operations (e.g., Consolidated Appropriations Act, 2026, impacting rebates and transparency), the Patient Protection and Affordable Care Act (ACA) affecting health benefit plans and minimum medical loss ratios, and healthcare fraud and abuse laws (e.g., False Claims Act, anti-kickback laws). Trade & Export Controls: The Company is subject to regulations by the U.S. Department of the Treasury's Office of Foreign Assets Control regarding economic sanctions and trade restrictions, as well as the Foreign Corrupt Practices Act (FCPA) and other anti-corruption laws in foreign jurisdictions. Legal Proceedings: The Cigna Group is routinely involved in legal matters, regulatory audits, and investigations related to its health services business, including claims concerning pharmaceutical dispensing, pharmacy benefit management, health benefit management, and provider services. In February 2026, the Company reached a final settlement with the FTC regarding alleged anticompetitive rebate practices related to insulin drug pricing, without monetary penalty or admission of liability. The Company is also subject to litigation regarding the use of AI in claims evaluation.

Tax Strategy & Considerations

Tax Profile: The Cigna Group's effective tax rate was 19.2% in 2025, down from 28.3% in 2024. Consolidated pre-tax income from foreign operations constituted approximately 53% of the Company's total pre-tax income in 2025. Tax Reform Impact: The Company is within the scope of the OECD Pillar Two Framework, which defines a minimum effective tax rate of 15%, but it did not have a significant impact on 2025 results and is not expected to significantly impact future periods. The Company benefits from renewable energy tax credits, which reduced its federal tax liability by $968 million in 2025. Uncertain Tax Positions: The Company maintains liabilities for uncertain tax positions, totaling $1.5 billion as of December 31, 2025, with an estimated $1.2 billion potentially payable in the future if positions are not sustained.

Insurance & Risk Transfer

Risk Management Framework: The Cigna Group manages its insurance risks through a combination of insurance coverage and risk transfer mechanisms. The Company procures third-party insurance, including excess liability coverage, and self-insures a significant portion of its litigation risks. Risk Transfer Mechanisms: The Company utilizes reinsurance arrangements with other insurance companies, primarily for acquisition or divestiture transactions. While reinsurance limits losses, The Cigna Group remains liable as the originating insurer. A notable example is the 2013 reinsurance transaction with Berkshire Hathaway Life Insurance Company of Nebraska, which effectively exited the variable annuity reinsurance business, with approximately $3.0 billion remaining under the overall limit as of December 31, 2025.